Psychoneurological symptoms during interferon therapy in patients with chronic hepatitis: Prospective study on predictive use of Cornell Medical Index and electroencephalogram

Liver International

Volumn 24, Issue 5, 2004, Pages 407-412

  Tanaka, Yuji ^a   Nagaki, Masahito ^a   Tomita, Eiichi ^b   Murase, Masahiko ^a   Enya, Masamichi ^b   Nishigaki, Yohichi ^b   Sugihara, Jun'ichi ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Gifu Municipal Hospital   (Japan)

Author keywords

Chronic hepatitis; Cornell Medical Index (CMI); Electroencephalogram (EEG); Interferon; Psychoneurological symptoms

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON A; ALPHA2A INTERFERON; ANTIDEPRESSANT AGENT; BETA INTERFERON; INTERFERON; NALOXONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ANAMNESIS; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMA; CONCENTRATION LOSS; CONSCIOUSNESS DISORDER; CONVULSION; DELIRIUM; DEPRESSION; DIAGNOSTIC ACCURACY; DISORIENTATION; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HYPOCHONDRIASIS; INSOMNIA; LETHARGY; MALE; MANIA; MEMORY DISORDER; MENTAL INSTABILITY; MOOD DISORDER; NEUROPSYCHOLOGY; ORGANIC BRAIN SYNDROME; PERSONALITY DISORDER; PROSPECTIVE STUDY; PSYCHOPATHY; PSYCHOTHERAPY; RESTLESSNESS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SLEEP DISORDER; VIRUS HEPATITIS; AGED; CHEMICALLY INDUCED DISORDER; ELECTROENCEPHALOGRAPHY; HEPATITIS B; HEPATITIS C; METHODOLOGY; MIDDLE AGED; NEUROSIS; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT;

ADULT; AGED; CORNELL MEDICAL INDEX; ELECTROENCEPHALOGRAPHY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; NEUROTIC DISORDERS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

EID: 16644385855     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0942.x     Document Type: Article

References (27)

1. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040-3.
2. Smedly H, Katrak M, Sikora K, Wheller T. Neurological effects of recombinant human interferon. Br Med J 1983; 286: 262-4.
3. Rohatiner A, Prior P, Burton A, Smith A, Balkwill F, Lister T. Central nervous system toxicity of interferon. Br J Cancer 1983; 47: 419-22.
4. Mattson K, Niiranen A, Iivanainen M, et al. Neurotoxity of interferon. Cancer Treat Rep 1983; 67: 958-61.
5. Suter C C, Westmoreland B F, Sharbough F W, Hermann R C Jr. Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc 1984; 59: 847-50.
6. Kamei S, Sakai T, Matsauura M, et al. Alterations of quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C. Eur Neurol 2002; 48: 102-7.
7. Kamei S, Tanaka N, Matsauura M, et al. Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Acta Neurol Scand 1999; 100: 25-33.
8. Brodman K, Erdman A J, Lorge I, Wolff H G. The Cornell Medical Index: an adjust to medical interview. JAMA 1948; 140: 530-4.
9. Kanehisa T, Fukamachi K, editors. Cornell Medical Index, 2nd Edn. Kyoto: Sankyoubo, 2001.
10. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-41.
11. Nakada Y. A study of psychosocial factors in the psychosomatic symptoms of adolescents in Okinawa. Acta Pediatr Jpn 1992; 34: 301-9.
12. Kaneko Y, Omae K. Effect of chronic exposure to acrylonitrile on subjective symptoms. Keio J Med 1992; 41: 25-32.
13. Miyasaki N, Yoshiuchi K, Yamanaka G, Sasaki T, Kumano H, Kuboki T. Relations among premorbid weight, referral weight, and psychological test scores for patients with anorexia nervosa. Psychol Rep 2003; 92: 67-74.
14. Renault P F, Hoofnagle J H, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577-80.
15. Hunt C M, Dominitz J A, Bute B P, Waters B, Blasi U, Williams D M. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482-6.
16. Malaguarnera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93-7.
17. Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12: 505-9.
18. Malaguarnera M, Laurino A, Di Fazio I, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-8.
19. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
20. Brenard R. Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg 1997; 60: 211-3.
21. Meyers C A, Scheibel R S, Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672 6.
22. Levenson J L, Fallon H J. Fluoxetine treatinent of depression caused by interferon -α. Am J Gastrtoenterol 1993; 88: 760-1.
23. Bonaccoroso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatr Res 2001; 105: 45-55.
24. Capuron L, Gumnick J F, Musselman D L, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-52.
25. Moldofsky H. Central nervous system and peripheral immune functions and the sleep-wake system. J Psychiatr Neurosci 1994; 19: 368-74.
26. Shintani F, Kanba S, Nakai T, et al. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 1993; 13: 3574-81.
27. Blalock J E, Smith E M. Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activty. Biochem Biophys Res Commun 1981; 101: 472-8.